Anticancer Activity of Naringenin on Human Liposarcoma: An Experimental and Bioinformatic Study Publisher Pubmed

Summary: Research suggests naringenin reduces liposarcoma cell growth. Could it be a new cancer therapy? #Liposarcoma #CancerResearch

Asghariazar V¹ ; Karimi A² ; Adeli S⁸ ; Kadkhodayi M^{3, 4} ; Zare E⁵ ; Vajdi M⁶ ; Nasimi Doost Azgoomi R⁷ ; Asghari Vostakolaei M⁷
Source: Prostaglandins and Other Lipid Mediators Published:2024

Abstract

Naringenin (NAR) has shown potential as a cancer treatment, reducing cell proliferation and invasion in soft tissue sarcomas like liposarcoma (LPS). This study investigates NAR's role and molecular mechanism. Bioinformatic analysis was performed to assess the expression level of genes in LPS based on the GEO dataset. The heat map and PPI of genes were also analyzed. MTT, wound healing, DAPI staining, and flow cytometry evaluated the cell viability, migration, and apoptosis. Besides, real-time PCR was used to measure the NAR's impact on the expression levels of EMT, apoptosis, inflammation, and metastasis-related genes. The results showed that NAR reduces cell viability, proliferation, and migration but induces apoptosis in LPS cells. RT-PCR results revealed that NAR is capable of regulating the expression level of the apoptosis, EMT, migration, and Inflammation-related genes. This study demonstrated that NAR may play a crucial role in reducing cell viability, inducing apoptosis, and attenuating migration in Sw872 LPS cells. Consequently, NAR might be a promising and efficient factor in the treatment of LPS. © 2024 Elsevier Inc.